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Abstract 
Around 12-15% of patients with locally advanced rectal cancer undergo a pathologically 
complete response (Tumour Regression Grade 4) to long course preoperative 
chemoradiotherapy; the remainder exhibit a spectrum of tumour regression (tumour 
regression grade 1-3). Understanding therapy-related transcriptional alterations may enable 
better prediction of response as measured by progression-free and overall survival, in addition 
to aiding the development of improved strategies based on the underlying biology of the 
disease. To this end we performed high-throughput gene expression profiling in 40 pairs of 
formalin fixed paraffin embedded rectal cancer biopsies and matched resections following long 
course preoperative chemoradiotherapy (discovery cohort). Differential gene expression 
analysis was performed contrasting tumour regression grades in resections. Enumeration of 
the tumour microenvironment cell population was undertaken using in silico analysis of the 
transcriptional data, and real-time PCR validation of NCR1 undertaken. 
Immunohistochemistry and survival analysis was employed to measure CD56+ cell 
populations in an independent cohort (n=150). Gene expression traits observed following long 
course preoperative chemoradiotherapy in the discovery cohort suggested an increased 
abundance of natural killer cells in tumours that displayed a clinical response to CRT in a 
tumour regression grade dependent manner. CD56+ natural killer cell populations were 
measured by immunohistochemistry and found to be significantly higher in tumour regression 
grade 3 patients compared to tumour regression grade 1-2 in the validation cohort. 
Furthermore, it was observed that patients positive for CD56 cells after therapy had a better 
overall survival (HR=0.282, 95%CI=0.109-0.729, χ
2
=7.854, p=.005). In conclusion, we have 
identified a novel post-therapeutic natural killer-like transcription signature in patients 
responding to long course preoperative chemoradiotherapy. Furthermore, patients with a 
higher abundance of CD56 positive natural killer cells post- long course preoperative 
chemoradiotherapy had better overall survival. Therefore, harnessing a natural killer-like 
response after therapy may improve outcomes for locally advanced rectal cancer patients.  
Abstract word count: 298 
Key words: 
Natural killer cells; rectal cancer; tumour regression; gene expression; chemoradiotherapy. 
 
Long course preoperative chemoradiotherapy for treatment of locally advanced rectal 
cancer typically consists of a fluoropyrimidine (5-fluorouracil or capecitabine) in 
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combination with 45-50.4 Grays of pelvic radiation over 5-5.5 weeks in 1.8Gy fractions 
with an interval of 8-12 weeks prior to total mesorectal excision. Following long course 
preoperative chemoradiotherapy, 12-15% of patients experience a pathologically 
complete response [1]. The remaining locally advanced rectal cancer patients exhibit 
a full spectrum of response from minimal residual malignancy to progressive disease. 
There are at least six published classification systems for locally advanced rectal 
cancer tumour regression [2]. However, many institutions have adopted the 4-tier 
tumour regression grade system similar to that published by Rodel et al 2005, due to 
its improved ability to predict prognosis and scoring concordance between 
pathologists. The extent of tumour regression after therapy has previously been 
associated with disease-free survival [3], therefore, an increased understanding of the 
biology that mediates tumour regression is crucial. Additionally identifying therapy-
related alterations to the tumour microenvironment architecture may provide guidance 
for alternative therapies for patients with poor outcomes. Modulation of key 
components of the immune system have observed in a variety of cancers treated 
preoperatively with radiotherapy and chemoradiotherapy, including sarcoma and 
rectal cancer. With regards to rectal cancer increased prevalence of CD3, CD4 and 
CD8 cell populations have been observed after long course preoperative 
chemoradiotherapy [4-7]. Based on these findings, we hypothesise that the 
transcriptome of post therapeutic tumour specimens and the tumour 
microenvironment will be representative of specific biology and thus may direct us to 
predictors of response to therapy.  
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Materials and Methods 
Clinical Specimens, Specimen annotation, Nucleic acid extraction 
Ethical permission for the study was authorised by the Northern Ireland Biobank 
(Research Ethics Committee number – 16/NI/0030. Project code: NIB13-0103). 60 
consecutive patients were identified who received long course preoperative 
chemoradiotherapy for locally advanced rectal cancer. Where available, formalin fixed 
paraffin embedded diagnostic biopsies (n=40) and the corresponding rectal resections 
(n=40) specimens were obtained from these patients. All patients received long course 
CRT comprising 45Gy/25 fractions over 5 weeks along with 5-Fluorouracil or 
capecitabine. Patients underwent total mesorectal excision at an interval of 1-14 
weeks (mean=9) following treatment. The clinical and pathological details of the 
patients are summarised in Supplementary Table 1. Tumour regression grade was 
scored using a four-tier system. Tumour regression grade 1 patients experience minor 
regression, tumour regression grade 2 patients experience significant regression, 
tumour regression grade 3 patients will have only small groups or single remaining 
malignant glands and tumour regression grade 4 will have no residual tumour after 
therapy.  All specimens have been assessed by a standardised protocol, whereby, if 
no tumour is evident macroscopically, then the site of tumour, and any scars of areas 
of ulceration, are processed in entirety for histological examination. Tumour regression 
grading was carried out by a colorectal specialist pathologist (ML). H&E stains of each 
specimen were annotated by a pathologist (MST) enriching for the epithelial 
compartment of both biopsy and resection, while including the fibro-inflammatory 
component immediately adjacent to the epithelial component.  
Total RNA was extracted using the RNeasy formalin fixed paraffin embedded kit 
(Qiagen) and genomic DNA was extracted using the DNeasy formalin fixed paraffin 
embedded kit (Qiagen). Integrity and purity of nucleic acids was assessed using the 
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Nanodrop 2000 (Thermofisher Scientific). Nucleic acids were quantified using the 
Qubit RNA HS Assay kit (Thermofisher scientific) and TaqMan RNase P Detection kit 
(ThermoFisher).   
Whole Genome DASL array and Real-Time (RT)-PCR 
Gene expression profiling was conducted on the Whole-Genome Gene expression 
DASL (cDNA-mediated, annealing, selection and ligation) high-throughput assay 
(Illumina) as reported elsewhere [8]. The RNA concentrations are detailed in 
Supplementary table 2 and the total input of RNA for each array was approximately 
50ng as quantified by Qubit (Thermofisher Scientific). This data is available via gene 
expression omnibus – accession GSE94104. Transcripts of interest were validated in 
samples were there was sufficient RNA remaining using Roche RealTime ready 
catalogue and designer assays; NCR1 (1000106257), SPANXA1 (100106293), 
GAPDH (100107995), and B2M (100108004). Reverse transcribed cDNA was 
generated using the First strand transcriptor kit (Roche) and pre-amplifed using the 
cDNA pre-amp kit (Roche) and assayed on the Roche Lightcycler 480 II. Suitable 
housekeeping genes were selected after assaying gene expression stability on a 
biopsy and tumour regression grade 1-3 resection specimens using the Human 
Reference Gene Panel (Roche). Gene expression fold changes (∆∆Cp Values) were 
calculated using the Second derivative method max instead of the fit point method for 
accurate quantification of low gene expression levels [9]. 
Immunohistochemistry 
All H&E stains were performed using the Sakura Autostainer. Immunohistochemistry 
was employed using the Bond Max (Leica microsystems) on formalin fixed paraffin 
embedded sections (3µm-thick) and stained with CD56 antibody NCL-L-CD56-1B6 
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(Novocastra) at a 1:100 dilution. Digital images were taken using the Aperio 
ScanScope (X40 magnification). Patients were considered to be CD56 positive if a 
single core had ≥4 positive cells; adopted from a CD56 immunohistochemistry tissue 
microarray scoring system published by Sconnochia et al 2014  [10]. 
Tissue Microarray 
Ethical permission was granted to investigate a post therapeutic rectal cancer tissue 
microarray provided by the Grampian Biorepository as a validation cohort (North of 
Scotland research ethics committee number - 11/NS/0015, Tissue request number 
TR71). The 150 patient resections were collected between 2005-2011 and all patients 
had long course chemoradiotherapy (45Gy) and concurrent capecitabine (825mg/m2 
twice daily) as pre-operative treatment [11]. The tissue microarray was constructed 
using two 1mm (0.79mm2) cores from each patient resection. The tumour regression 
grading of these samples was conducted using a similar classification system 
(Complete response, good partial, partial and minimal) by an expert gastrointestinal 
pathologist (G.I.M) allowing an easy conversion into the tumour regression grade 1-4 
classification system adopted in our own study. The clinical and pathological details of 
the patients in this cohort are summarised in Supplementary Table 3. Patient all-
cause mortality was identified from interrogation of the electronic hospital 
patient information system where status (alive/dead) was recorded. At the time of 
censoring of patient outcome data, there had been 35 (23.5%) deaths. The mean 
patient survival was 72 months [95% confidence interval (CI) 68–75 months]. Clinical 
follow-up was a minimum of 19 months up to maximum of 99 months. 
Exclusion criteria and comparative assessment 
The inclusion and exclusion process of patients in the discovery and validation cohorts 
is outlined in the consort diagram in figure 1. All tumour regression grade 4 patients 
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were excluded from the discovery cohort (n=5), as were patients that tumour had been 
exhausted by serial sectioning (n=12). A further three patients failed to produce 
transcriptional profiles. Similarly for the validation cohort tumour regression grade 4 
patients were excluded from subsequent analysis (n=73) as were cores that lacked 
tumour with excessive fibrosis, muscle and mucin (n=98) which was in-line with the 
approach for transcriptional profiling of NIB13-0103 cohort.  
Comparative assessment of clinical and pathological parameters of both patient 
cohorts demonstrated their suitability as clinically representative discovery and 
validation cohorts for investigating tumour regression in locally advanced rectal 
cancer. Patient specimens were obtained for the NIB13-0103 discovery cohort 
between 2004-2013 from the Belfast Health and Social Care Trust while the patient 
specimens from the validation cohort were collected between 2005-2011 by NHS 
Grampian. Only patients who received long course preoperative chemoradiotherapy 
consisting of fluoropyrimidines and 45Gy pelvic radiation and for whom there was 
sufficient tumour available for molecular and tissue analysis were included in the 
study.   
Statistical analysis 
Assessing statistically significant differences between variables was determined using 
the Students t test, Log-rank test, Chi-squared and Cox multivariate analysis. Survival 
was assessed using the Kaplan-Meier method assessed in SPSSv23 for windows. P-
values <.05 were considered significant. 
 
High-throughput gene expression analysis 
The high-throughput gene expression dataset was exported using Illumina Genome 
studio. Data was background corrected and normalised using positive, negative and 
housekeeping controls from the WG-DASL assay automatically provided by Partek’s 
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Report Plug-in. Principal components analysis, differential gene expression analysis 
(ANOVA between tumour regression grade 1 vs tumour regression grade 3) and 
hierarchical clustering analysis were conducted using Partek® Genomics 
Suite® software, version 6.6 Copyright ©; 2016. Differentially expressed genes were 
determined using fold change thresholds ranging between 2 and 10-fold expression 
change and only genes with an adjusted p-value <0.05 (Benjamini-Hochberg) were 
reported. Heat maps with hierarchical clustering were constructed using Ward’s 
linkage and Euclidean distance. Row expression values were standardised to a mean 
of zero and scaled to a standard deviation of one.  Ingenuity Pathway Analysis and 
Gene Set Enrichment Analysis (http://software.broadinstitute.org/gsea/index.jsp) were 
used for biological interpretation of differentially expressed genes. 
Next Generation Sequencing 
Mutational status was acquired from patient biopsies from approximately 10ng DNA. 
Sequencing was performed using the Ion Torrent Personal Genome machine, as 
previously published [12]. Only 38/40 patients had successful mutational profiles 
generated. 
Defining microsatellite instability 
Microsatellite instability was assessed using MSI Analysis system, Version 1.2 
(Promega) on the Applied Biosystems 3500 analyser (Thermofisher Scientific) using 
Genemapper v4.1 software. Microsatellite instability was determined by the instability 
of two or more of the five markers (NR24, BAT26, NR21, BAT25 and MONO27) [8]. 
Microenvironment Cell Populations Counter 
Microenvironment cell population counter is a peer reviewed software tool that robustly 
measures the abundance of microenvironment cell populations using transcriptional 
data generated from heterogeneous tissues. The microenvironment cell population 
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counter R package was downloaded from - http://cit.ligue-
cancer.net/?page_id=1243&lang=en. An estimate score for NK cells which equates to 
the absolute abundance of cell type was generated for each NIB13-0103 
transcriptional profile [13]. 
QUADrATiC Analysis 
The 27 gene signature generated from differential gene expression analysis in 
Partek® Genomics Suite® software, version 6.6 Copyright ©; (see Supplementary 
Table 4) was used to perform connectivity map analysis using the QUADrATiC 
software [14]. The 27 genes were mapped using annotation files to probe IDs for the 
Affymetrix HG U133A microarray, since QUADrATiC requires its input signatures in 
this form. Running the analysis produces a candidate list of positive connections, i.e. 
those FDA-approved compounds within the LINCS database which appear to induce 
similar expression patterns to that of the 27 genes, in particular cell lines. This 
candidate list was further investigated for any compounds with immune-modulating 
properties.  
Results 
Comparative analysis of the discovery and validation cohorts revealed no statistically 
significant differences observed between the proportions of regression grades (tumour 
regression grade 3 27.5% vs 37%, tumour regression grade 2 42.5% vs 46%, tumour 
regression grade 1 30% vs 17%), as determined by Chi-squared (p= 0.147). This 
ensured no regression-related sample enrichment or bias in our selected sample sets.  
Unsupervised principal components analysis was employed to visualise gene 
expression data from the NIB13-013 post-therapeutic resection specimens (Figure 
2A). The principal components analysis plot highlighted a distinct separation between 
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post-treatment profiles from tumour regression grade 1 and 3 patients with an overlap 
of tumour regression grade 2 patients with both groups which highlights major 
differences in gene expression across the patient cohort. Using these tumour 
transcriptomic profiles we conducted differential gene expression analysis to identify 
specific genes of interest for downstream investigation by comparing tumours with 
either tumour regression grade 1 or tumour regression grade 3 response. Using this 
supervised approach, we identified 27 genes which had over 10-fold differential 
expression changes between our contrasting tumour regression grade subgroups. In 
order to test the robustness of classifying samples based on tumour regression grade, 
we used this 27 gene signature generated from contrasting tumour regression grade 
1 with tumour regression grade 3, to classify tumour regression grade 2 tumours. 
Importantly, we found that our signature clustered tumour regression grade 2 tumours 
as having intermediate signature expression compared to tumour regression grade 1 
and tumour regression grade 3, indicating a dose response of expression according 
to tumour regression grade and confirming its potential clinical utility (Figure 2B). The 
27 genes consisted of natural killer cell receptors, cancer/testis antigens, olfactory 
receptors, and solute carriers (supplementary table 4). Ingenuity pathway analysis of 
the 27 genes suggested that “Natural Killer Cell signalling” and “Crosstalk between 
Dendritic Cells and Natural Killer Cells” are the two defining pathways involved with 
this tumour regression grade associated gene list (Figure 2C).   
To identify potential FDA-approved compounds that may induce the gene expression 
phenotype of responders after therapy and harness the good prognosis natural killer-
like biology, we utilised the QUADrATiC software. QUADrATiC requires an input of 
Affymetrix probe IDs. Therefore, the analysis was performed using 21 Affymetrix probe 
IDs that could be matched from the 27 Illumina probe IDs identified.  Statistically 
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significant positive connection scores were generated for the immunomodulatory drug 
(IMiD) Lenalidomide and the proteosomal inhibitor bortezomib (Supplementary figure 
1a). Both of these agents are already established in routine clinical practice in the 
treatment of haematological malignancies [15,16]. The heatmap shows the relative 
contribution (or Contribution Fraction) of each individual probes input to the overall 
score and we can conclude from this that the cancer-testis antigen families SPANX 
and GAGE were the most significant contributors to the connection scores and hence 
are potential targets for the mechanism of action of the two drugs (Supplementary 
figure 1a).  This result prompted us to cluster resection specimens based upon the 
expression of a list of cancer testis antigens genes. Robust clustering in a tumour 
regression grade dependent manner was observed with a higher expression in the 
responders (tumour regression grade 3) than in tumour regression grade 1/non-
responders (Supplementary figure 1b). We selected the cancer testis antigen 
SPANXA1 to validate using RT-PCR. Results indicated that the average fold change 
between the tumour regression grade 1 group and tumour regression grade 3 patient 
group was 7.3 (Supplementary figure 1c).  
Based upon our observations, microenvironment cell population counter was used to 
assess the abundance of natural killer cells in our resection specimens. Where we 
observed significantly increased natural killer cell populations in a tumour regression 
grade dependent fashion (figure 3A, p <0.0001, Tukey’s multiple comparisons test). 
This finding was complemented by gene set enrichment analysis comparing tumour 
regression grade 3 vs tumour regression grade 1 resection transcriptional profiels 
which showed a statistically significant upregulation of the 
“GO_NATURAL_KILLER_CELL_ACTIVATION” gene set in tumour regression grade 
3 resections (Figure 3B). Subsequently, validation of the natural killer cell specific 
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marker NCR1 which emerged as a differentially expressed gene was performed using 
RT-PCR. There was observed to be a statistically significant 2.3 fold difference in 
expression between tumour regression grade 3 and tumour regression grade 1 
patients (figure 3c, p= 0.04). The cell surface protein NCAM1 also known as CD56 is 
considered one of the most specific proteomic markers for natural killer cells. A 
number of remaining resections with viable tumour from the discovery cohort were 
stained by immunohistochemistry for the natural killer cell marker CD56, confirming 
the presence of CD56 positive cells in a tumour regression grade 3 resection 
(Figure3D). Interestingly, NCAM1 is considered a poor marker of natural killer cells at 
the transcript level due to its non-specific expression, as it is also strongly expressed 
by nerve ganglion and for this reason it is not included as a marker of natural killer cell 
quantification in microenvironment cell population counter [13]. Supplementary figure 
2 supports this finding as it was observed that the expression of NCAM1 is not tumour 
regression grade dependent in our cohort unlike the natural killer cell marker NCR1. 
We next examined the transcriptional profiles obtained for the matched pre-treatment 
biopsies and assessed the abundance of natural killer cells, again using 
microenvironment cell population counter. It was observed that the presence of natural 
killer cells in pre-treatment biopsies was not tumour regression grade dependent and 
therefore did not have predictive value (figure 4a). A trend was observed that the 
abundance of natural killer cells tended to increase in tumour regression grade 3 
patients in a matched pre and post analysis while tumour regression grade 1 patients 
experienced increases and decreases in the abundance of natural killer cells, however 
this did not reach statistical significance (figure 4b+c).   
Next generation sequencing analysis of clinically relevant mutations (KRAS, TP53, 
BRAF, NRAS, APC, ERBB2, PIK3CA, and SMAD4) was performed to assess any 
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association with mutational profile and the presence of our natural killer-like gene 
expression signature. There was no observable association between our mutational 
data and the tumour regression grade dependent transcriptional subgroups identified, 
which is highlighted by a heatmap that depicts the mutations present in each tumour 
regression grade (supplementary figure 3). We also performed a comparative analysis 
to identify differences in the mutational landscape of the NIB13-0103 rectal cohort 
(n=38) when compared to the TCGA, Nature 2012 colorectal cancer dataset. [17,18]. 
The dataset was filtered for rectal cancer stage II-III (n=31) using cBioPortal. This 
comparison of mutations in the NIB13-0103 and TCGA cohorts demonstrated no 
statistical difference in the proportions of mutations of TP53 (73.68% vs 80.65%, p = 
0.547), KRAS (55.26% vs 45.16.0% p= 0.472), APC (39.47% vs 77.42.0% p= 0.283 ), 
NRAS (0% vs 6.45% p = 0.198), BRAF (2.63% vs 0% p = 1.0 ), ERBB2 (0% vs 6.45% 
p= 0.198), PIK3CA (5.26% vs 9.68% p = 0.651), SMAD4 (7.89% vs 3.23% p =0.622) 
[17,18]. However, interpretation of these differences is difficult considering the small 
sample size of both cohorts. Similarly, we could not determine an association between 
MSI status in our patients and the natural killer-like response as no tumours were MSI 
high. 
In order to confirm the gene expression findings using a diagnostically relevant 
methodology, we performed an immunohistochemistry-based assessment of 
resection tumour samples from an independent rectal cancer cohort (n=150) using the 
NK marker CD56. We observed a significantly higher total number of CD56+ cells per 
core in the tumour regression grade 3 resections compared to the number of CD56+ 
cells in tumour regression grade 1 resection specimens (p value = 0.008) (Figure 5a-
d). The prognostic significance of CD56 positivity was investigated in this independent 
cohort, with patients categorised as CD56 positive when ≥4 positive cells per core 
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were observed. Using this threshold for positivity, patients with CD56 positivity were 
shown to have a significantly better overall survival (HR=0.282, 95%CI=0.109-0.729, 
χ
2
=7.854, p=.005), which was independent of tumour regression grading (Figure 6A).  
Interestingly CD56 positivity conferred a trend towards better outcomes within all 
tumour regression grades, particularly within the tumour regression grade 1 samples 
within the independent cohort (Figure6b-d). Furthermore, CD56 positivity was shown 
to be independently prognostic through multivariate analysis p<.006 (supplementary 
table 5).  
Discussion 
It has been proposed that common alterations to immune/inflammatory pathways may 
confer sensitivity to long course preoperative chemoradiotherapy in locally advanced 
rectal cancer patients [19]. Understanding the nature of the immune response that 
occurs following long course preoperative chemoradiotherapy may be problematic in 
pre-therapeutic biopsies. Therefore, we have interrogated post-therapeutic locally 
advanced rectal cancer resections using a combination of modern high-throughput 
genomic technologies and traditional pathology techniques, to characterise the 
immune response that has occurred and allow us to hypothesise its use a predictive 
biomarker in on-treatment biopsies but also how harness it for therapeutic benefit.  
Both radiation and chemotherapy can augment immune response possibly through 
increased expression of antigens [8], these antigens may be responsible for engaging 
the cytotoxic cells of the adaptive immune system [9-11]. The increased presence of 
CD8+ cytotoxic lymphocytes are well defined in colorectal cancer particularly in 
microsatellite unstable tumours and are associated with an improved prognosis [12]. 
Based upon the expression of immune checkpoints such as PDL1 there is rationale 
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for the use of immune checkpoint inhibitors in MSI-H colorectal cancers and although 
most immune checkpoint inhibitors execute their effects through CD8+ cytotoxic 
lymphocytes, therapeutic modulation of other immune cell types such as 
macrophages, myeloid-derived suppressor cells and natural killer cells could have 
similar effects in the rectal paradigm [13-15].  Natural killer cells are cytotoxic 
lymphocytes of the innate immune system and act as the body’s first line of defence 
against tumour cells. Natural killer cells have been observed to be critical for response 
to gemcitabine in pancreatic mouse models [16]. Furthermore, the presence and 
activity of natural killer cells may be an indicator of favourable outcome in breast 
cancer and oropharyngeal squamous cell carcinoma [17,18]. 
In this study we observed significantly increased expression of genes associated with 
a natural killer-like phenotype after long course preoperative chemoradiotherapy. This, 
to our knowledge, is a novel observation following treatment of locally advanced rectal 
cancer. While the overall frequency of these cells may not be very high, they do appear 
to be associated with a strong biological response underpinning their potential 
biological significance and implications in tumour regression. The presence of natural 
killer cells was initially defined in silico using the microenvironment cell population 
counter tool which gives a robust estimation to the abundance of NK cells [13]. The 
abundance of natural killer cells was also assessed in the pre-therapeutic biopsies, 
however increased natural killer cells was shown to be therapy related and therefore 
not a predictive biomarkers of response. Validation of the microarray results was 
performed by employing RT-PCR using NCR1. The expression of NCR1 is considered 
one of the more specific markers of natural killer cells, however natural cytotoxicity 
receptors can also be expressed on innate lymphoid cells [20,21]. The delineation of 
classical natural killer cell populations from iNKT cells, mucosal associated invariant 
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T cells, ILC1s, ILC3s and gamma delta T cells remains challenging in formalin fixed 
paraffin embedded tissue as there is considerable overlap in the receptor repertoires, 
and as such cell specific detailing still relies on flow cytometry approaches [22-26]. 
Therefore, the general expression of immune derived CD56 still remains the gold 
standard for detecting natural killer cells in formalin fixed paraffin embedded tissue. 
As a result of our gene expression profiling we investigated the expression of the 
natural killer cell marker CD56 using immunohistochemistry. A comprehensive 
analysis of CD56 natural killer cell expression of post-therapeutic resection specimens 
could not be performed in the discovery cohort due to tumour exhaustion in many of 
the tumour regression grade 3 specimens through serial sectioning of the formalin 
fixed paraffin embedded blocks. However CD56 immunohistochemistry was 
successfully employed in the validation cohort and we observed this cell type to be 
more frequent in tumour regression grade 3 responders than tumour regression grade 
1 after therapy. Our evaluation of CD56 immunohistochemistry was performed on 
tissue microarray cores which is a limitation of this study due to potential regional bias, 
therefore, we feel that further adjusting our scoring criterion to enable CD56 
assessment in full resection specimens deserves further investigation. The presence 
of CD56+ natural killer cells by immunohistochemistry in treatment naïve colorectal 
cancer has been described as infrequent [27,28]; on this basis we did not discern 
between those in the adjacent-stroma and intraepithelial natural killer cells, however, 
in a larger dataset of full face resection specimens we would prefer to assess the 
influence of different regional infiltration. 
A recent study demonstrated the clinical importance of natural killer cells in colorectal 
cancer, Sconocchia et al 2014 observed that an enrichment of both natural killer and 
CD8 T cells improved the outcome of colorectal cancer patients [10]. With regards to 
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post therapeutic infiltration of immune cells in rectal cancer, the presence of natural 
killer cells has not previously been observed to be significant in post therapy rectal 
specimens by CD56+ immunohistochemistry [7]. However, it is worth noting in this 
study, positive infiltration of CD56 natural killer cells was assessed as 4>/high powered 
field rather than ≥4 positive cells per core which may account for different 
observations. Post-therapeutic infiltration of adaptive immune cells in locally advanced 
rectal cancer has been shown to increase after therapy, Teng et al 2015 observed 
significantly higher CD3 and CD8 TILs and in a further study also CD4 tumour 
infiltrating lymphocytes [6,7].  
It is evident that the clinical utility of measuring natural killer cell density in pre-
treatment locally advanced rectal cancer biopsies may be limited. However, our 
observation of tumour regression grade dependent natural killer cell abundance in 
post-therapeutic resections warrants the collection and analysis of on-treatment or 
post-therapeutic biopsies in order to assess natural killer cell biology that may have 
the potential to provide real-time clinical guidance on the efficacy of the therapeutic 
intervention. We observed that patients with CD56 positivity had a significantly better 
outcome to chemo-radiation than those with lower levels of CD56 staining with 
multivariate analysis showing CD56 positivity to be a significant independent 
prognostic factor. As a result, we hypothesise that encouraging this natural killer cell 
biology with immune modulating compounds may be a novel therapeutic strategy for 
locally advanced rectal cancer patients.  
By using QUADrATiC software to carry out connectivity mapping analysis against the 
subset of FDA-approved compounds in the LINCs database, we identified 
Lenalidomide and Bortezomib as two FDA approved compounds with proven anti-
tumour and immunomodulatory effects that may induce the expression of the 27 genes 
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identified in Supplementary Table 4. Lenalidomide and proteosomal inhibitors 
(Bortezomib and Carfilzomib) are already in clinical use for the treatment of 
haematological malignancies and have demonstrated the ability regulate natural killer 
cell function. [15,16,29-33]. By analysing the connections further using the Contribution 
Fraction capabilities of QUADrATiC, both compounds were shown to have an 
association with the increased expression of cancer testis/antigens which are 
potentially activators of T cell receptor mediated cytotoxicity, and thus may play a role 
in therapy-related immunomodulation [4,5].  
We hypothesise that using immune modulating compounds such as lenalidomide and 
low dose bortezomib (or the second generation proteosomal inhibitor Carfilzomib) as 
single agents or even in combination could prime the natural killer cell-related immune 
system, improving the efficacy of standard chemoradiotherapy. Aside from immune 
modulating compounds such as bortezomib and lenalidomide, there are currently 
three other methods of stimulating or harnessing natural killer cell function i) 
endogenous interleukins such as IL-2 and IL-15, can stimulate natural killer cell activity 
[34], ii) monoclonal antibodies that act as natural killer cell immune checkpoint 
inhibitors such as Lirilumab [35] iii) autologous and allogeneic transfer of wild type and 
genetically engineered natural killer cells are also being tested for efficacy in both 
haematological and solid tumours [36-38]. 
In conclusion, we have provided independently validated evidence that the presence 
of a CD56+ natural killer-like immune response after therapy confers better overall 
survival for locally advanced rectal cancer patients, which may also be independent of 
tumour regression. We can conclude that natural killer cells are an important element 
of the immune landscape of locally advanced rectal cancer and on this basis we have 
hypothesised that harnessing a natural killer cell response using immune modulating 
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compounds could further improve outcomes for patients with locally advanced rectal 
cancer. Finally, real-time longitudinal assessment of the natural killer cell response in 
on-treatment biopsy material may inform clinical decision-making for duration of 
treatment or surgical decision to remove tumour if no response to long course 
preoperative chemoradiotherapy is evident. 
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Figure Legends 
Figure 1. Consort diagram outlining the inclusion and exclusion process for 
discovery (matched pre-treatment biospies and post-therapeutic resections 
n=40) and validation cohort (post-therapeutic tissue microarray n=150) prior to 
data generation and analysis  
Figure 2. Differential gene expression analysis and Pathway Analysis of locally 
advanced rectal cancer resections in discovery cohort (n=40). (A) Principal 
Component Analysis of locally advanced rectal cancer resections by tumour 
regression grade shows separation of tumour regression grade 1 gene expression 
profiles and tumour regression grade 3 profiles. (B) Heatmap showing hierarchical 
clustering analysis of resections by 27 most differentially expressed genes, (blue 
denotes down-regulated expression of genes and red upregulation), the heatmap 
depicts an upregulation of these genes in tumour regression grade 3 resections (C) 
Ingenuity Pathway Analysis of 27 genes, Bar chart shows natural killer cell signalling 
to be the most statistically enriched pathway. Legend - tumour regression grade 1 
(red), tumour regression grade 2 (yellow) and tumour regression grade 3 (blue). 
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Figure 3. Assessing natural killer cell biology in locally advanced rectal cancer 
resections of discovery cohort (n=40). (A) Microenvironment cell population 
counter NK cell estimate scores assessed in post therapeutic locally advanced rectal 
cancer resections (tumour regression grade 1 vs tumour regression grade 3, p 
<0.0001) demonstrates a higher abundance of natural killer cells in tumour 
regression grade 3 resections when compared to tumour regression grade 1. (B) 
Gene Set Enrichment Analysis  comparing tumour regression grade 3 resections 
(phenotype 1) and tumour regression grade 1 resections (phenotype 0) using the 
GO_NATURAL KILLER_CELL_ACTIVATION gene set (FDR < 0.0001), shows an 
upregulation of genes associated with natural killer cell activity in tumour regression 
grade 3 resections compared to tumour regression grade 1 (C) RT-PCR validation of 
mRNA expression of NCR1 in tumour regression grade 1 + tumour regression grade 
3 rectal resections. (p = 0.04, students t test). (D) Image depicting CD56 positive 
natural killer cells by immunohistochemistry in tumour regression grade 3 post-
therapeutic resection from the discovery cohort (x40 magnification).  
Figure 4. Assessing the abundance of NK cells in biopsies and matched 
resections in discovery cohort (n=40) using microenvironment cell population 
counter. (A) Microenvironment cell population counter NK cell estimate scores 
assessed in pre therapeutic locally advanced rectal cancer biopsies shows no 
difference in abundance of natural killer cells between tumour regression grades (B) 
Normalised microenvironment cell population counter NK cell estimate scores 
assessed in pre therapeutic tumour regression grade 1 locally advanced rectal 
cancer biopsies and matched resections shows changes after long course 
preoperative chemoradiotherapy (C) Normalised microenvironment cell population 
counter NK cell estimate scores assessed in pre therapeutic tumour regression 
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grade 3 locally advanced rectal cancer biopsies and matched resections shows 
changes after long course preoperative chemoradiotherapy. 
Figure 5. The association between CD56 positive natural killer cells and tumour 
regression grade in post-therapeutic validation locally advanced rectal cancer 
tissue microarray (n=150) using immunohistochemistry. (A) Dot plot showing 
total counts of CD56 positive natural killer cells per tissue microarray core grouped 
by tumour regression grading (tumour regression grade 3 vs tumour regression 
grade 1). There was observed to be significantly more CD56 positive natural killer 
cells in tumour regression grade 3 resections compared to tumour regression grade 
1 resections by students T test p = 0.0083. (B) Representative image of a CD56 
positive immunohistochemistry in tissue microarray core of a tumour regression 
grade 3 responder with CD56 natural killer cells highlighted in yellow (x40 
magnification). (C) Representative image of a CD56 positive tissue microarray core 
by immunohistochemistry of a tumour regression grade 1 responder with CD56 
natural killer cells highlighted in yellow (x40 magnification). 
 
Figure 6. Investigating the influence of CD56 immunohistochemistry positivity 
on overall survival in post-therapeutic locally advanced rectal cancer 
validation tissue microarray (n=149)*. (A) Kaplan-Meier Curves showing overall 
survival of all patients (tumour regression grade 1-3) based upon CD56 positivity 
(HR=0.282, 95%CI=0.109-0.729, χ2=7.854, Log-rank p= 0.005). (B) Kaplan-Meier 
Curves showing overall survival of CD56 positive patients within tumour regression 
grade 3 subgroup (HR=0.404, 95%CI=0.081-2.004, χ2=1.317, Log-rank p= 0.251). 
(C) Kaplan-Meier Curves showing overall survival of CD56 positive patients within 
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tumour regression grade 2 subgroup (HR=0.323, 95%CI=0.094-1.109, χ2=3.621, 
log-rank p= 0.057) (D) Kaplan-Meier Curves showing overall survival of CD56 
positive patients within tumour regression grade 1 subgroup (HR=0.036, 
95%CI=0.000-116.410, χ2=1.677, log-rank p= 0.195). * One patient from CD56 
immunohistochemistry validation tissue microarray did not have survival data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
